Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3274

Shown on this page

Current sort

Live official records

Open in full search

Conditions: COVID-19 Infection
Interventions: ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 70
States / cities: Canoga Park, California • Granada Hills, California • La Jolla, California + 26 more

Conditions: Acute Treatment of Migraine
Interventions: Rimegepant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Canoga Park, California • Fresno, California • Los Angeles, California + 16 more

Conditions: RSV Infection
Interventions: RSVpreF, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more

Conditions: Pneumococcal Disease
Interventions: PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 29 more

Conditions: Hemophilia A, Hemophilia B
Interventions: marstacimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: mCRPC
Interventions: Talazoparib with enzalutamide, Placebo with enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more

Conditions: Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: ponsegromab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more

Conditions: Advanced Malignancies, Advanced Cancer
Interventions: PF-07994525, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Denver, Colorado • New Haven, Connecticut • North Haven, Connecticut + 10 more

Conditions: Cervical Cancer
Interventions: TIVDAK; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 131
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 70 more

Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more

Conditions: Prostate Cancer
Interventions: talazoparib plus enzalutamide, Placebo plus enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 11
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

About this Pfizer sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Pfizer clinical trials

Filter and sort this sponsor

Live official records

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

About this Pfizer sponsor directory page